多塔利单抗联合化疗在dMMR/MSI-H原发性晚期或复发性子宫内膜癌患者中的疗效与安全性:一项3期随机安慰剂对照试验(ENGOT-EN6-NSGO/GOG-3031/RUBY)
RUBY试验第1部分的多塔利单抗联合卡铂-紫杉醇对比安慰剂联合卡铂-紫杉醇在dMMR/MSI-H原发性晚期或复发性子宫内膜癌患者中的疗效与安全性分析。共纳入118例dMMR/MSI-H患者(多塔利单抗组53例,安慰剂组65例)。研究者评估显示多塔利单抗联合卡铂-紫杉醇使疾病进展或死亡风险降低72%(P<0.0001),与盲法独立中心审查结果一致,安全性与此前总体人群报告相似。
要点
- 多塔利单抗联合卡铂-紫杉醇使dMMR/MSI-H子宫内膜癌进展或死亡风险降低72%(P<0.0001)。
- 研究者评估的无进展生存获益与盲法独立中心审查结果一致。
- 安全性结果与既往总体人群报告相似。
核心结论
- 所有主要和次要疗效评估均显示多塔利单抗联合卡铂-紫杉醇具有一致的获益,生存改善及可控的安全性支持该方案在dMMR/MSI-H原发性晚期或复发性子宫内膜癌患者中具有有利的获益-风险特征。
研究设计与样本
- RUBY试验(NCT03981796)第1部分为3期随机安慰剂对照试验,患者按1:1随机接受多塔利单抗500 mg或安慰剂联合卡铂-紫杉醇,每3周一次共6个周期,随后多塔利单抗或安慰剂每6周一次,最长3年。
- dMMR/MSI-H人群共纳入118例患者(多塔利单抗组53例,安慰剂组65例)。
- 分析包括研究者评估对比盲法独立中心审查的无进展生存期、源数据验证人群对比随机人群的敏感性分析以及该人群的安全性分析。
主要发现
- 在首次 interim 分析中,研究者根据RECIST v1.1评估,多塔利单抗联合卡铂-紫杉醇使疾病进展或死亡风险降低72%(P<0.0001),与盲法独立中心审查结果一致。
- 源数据验证的dMMR/MSI-H人群对比随机dMMR/MSI-H人群的敏感性分析显示无进展生存期和总生存期结果一致。
- dMMR/MSI-H人群的安全性结果与既往总体人群报告相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Part 1 of the RUBY trial (NCT03981796) demonstrated improved survival in patients with primary advanced or recurrent endometrial cancer (EC) treated with dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel. Here, we examine additional efficacy and safety data from patients with mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) EC in the RUBY trial. METHODS: Patients were randomized 1:1 to dostarlimab 500 mg or placebo plus carboplatin-paclitaxel every 3 weeks for 6 cycles followed by dostarlimab or placebo every 6 weeks for up to 3 years. In the dMMR/MSI-H population of RUBY Part 1, analysis of progression-free survival by investigator assessment compared with blinded independent central review, sensitivity analyses of the source-verified population compared with the randomized population, and analysis of safety in this population were completed. RESULTS: In total, 118 patients with dMMR/MSI-H were enrolled in the RUBY trial (53, dostarlimab arm; 65, placebo arm). At the first interim analysis, a 72% reduction in the risk of progression or death (P < 0.0001) was seen with dostarlimab plus carboplatin-paclitaxel by investigator assessment per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), which was consistent with blinded independent central review per RECIST v1.1. Likewise, sensitivity analyses of the source-verified dMMR/MSI-H population compared with the randomized dMMR/MSI-H population were consistent for progression-free survival and overall survival. Safety results seen in the dMMR/MSI-H population were similar to those previously reported for the overall population. CONCLUSIONS: All primary and secondary efficacy assessments demonstrate the consistent benefit of dostarlimab plus carboplatin-paclitaxel. The improvements seen in survival and the manageable safety profile support the favorable benefit-risk profile for dostarlimab plus carboplatin-paclitaxel in patients with dMMR/MSI-H primary advanced or recurrent EC.
引用
- Powell MA, Cibula D, O'Malley DM, et al. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gynecol Oncol. 2024. PMID: 39531903. doi:10.1016/j.ygyno.2024.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。